Progressive Supranuclear Palsy

About Progressive Supranuclear Palsy (PSP)

Progressive Supranuclear Palsy (PSP) is a Parkinsonian neurological condition caused by the premature loss of nerve cells in certain parts of the brain, which leads to difficulties with balance, movement, vision, speech and swallowing.

IXICO has supported clinical trials in this area since 2015 having provided advanced analytics for 5 clinical trials across 230 global sites. As a rare disease, several new treatments for PSP have been granted orphan drug status by the FDA, fuelling momentum in PSP research.

Industry Leaders in Progressive Supranuclear Palsy Imaging

  • The industry leaders in image data science supporting Progressive Supranuclear Palsy clinical trials in all phases of drug development.

PSP specific validated regional analysis

  • Progressive Supranuclear Palsy specific validated volumetric image endpoints using IXICO’s proprietary LEAP algorithm.

Expert neuroradiology

  • Team of expert Neuro-radiologists performing centralised, real time, standardised safety reads assessing for Progressive Supranuclear Palsy specific visual pathologies.


Consultation and Supporting Regulatory Pathway

  • Protocol consultation at early stage to support Regulatory pathway.
  • Dedicated team of project managers and scientists with therapeutic area expertise in Progressive Supranuclear Palsy.